Published in Medical Letter on the CDC and FDA, September 5th, 2004
Truvada combines 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate in one tablet, taken once a day in combination with other antiretroviral agents.
Gilead also announced that it has received clearance from the FDA for an alternate trade dress for Truvada for use in the developing world. The company plans to include Truvada in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.